P1101
Showing 1 - 25 of 1,110
Polycythemia Vera (PV) Trial in Japan (P1101, Low-dose aspirin, Phlebotomy)
Not yet recruiting
- Polycythemia Vera (PV)
- P1101
- +2 more
-
Mie, Japan
- +5 more
Aug 15, 2023
Polycythemia Vera Trial (Ropeginterferon alfa-2b-njft (P1101))
Not yet recruiting
- Polycythemia Vera
- Ropeginterferon alfa-2b-njft (P1101)
- (no location specified)
Jul 28, 2022
Essential Thrombocythemia Trial (Ropeginterferon alfa-2b-njft (P1101))
Not yet recruiting
- Essential Thrombocythemia
- Ropeginterferon alfa-2b-njft (P1101)
- (no location specified)
Jul 28, 2022
Polycythemia Vera (PV) Trial in Japan (P1101 (Ropeginterferon alfa-2b))
Recruiting
- Polycythemia Vera (PV)
- P1101 (Ropeginterferon alfa-2b)
-
Toon-shi, Ehime, Japan
- +5 more
Jun 13, 2022
Chronic Hepatitis B Virus Infection Trial in Kaohsiung, Taichung, Taipei (Ropeginterferon alfa-2b, Entecavir)
Recruiting
- Chronic Hepatitis B Virus Infection
- Ropeginterferon alfa-2b
- Entecavir
-
Kaohsiung, Taiwan
- +4 more
Aug 12, 2022
Primary Myelofibrosis, Secondary Myelofibrosis Trial in Scottsdale (Laboratory Biomarker Analysis, Quality-of-Life Assessment,
Active, not recruiting
- Primary Myelofibrosis
- Secondary Myelofibrosis
- Laboratory Biomarker Analysis
- +2 more
-
Scottsdale, ArizonaMayo Clinic in Arizona
Jan 7, 2022
Hepatocellular Carcinoma Trial in Taipei city (P1101 (Ropeginterferon alfa-2b), Nivolumab)
Recruiting
- Hepatocellular Carcinoma
- P1101 (Ropeginterferon alfa-2b)
- Nivolumab
-
Taipei city, TaiwanNational Taiwan university Hospital
Jan 25, 2022
Hepatitis C, Chronic Trial in Taiwan (P1101 + Ribavirin)
Recruiting
- Hepatitis C, Chronic
- P1101 + Ribavirin
-
Chiayi City, Taiwan
- +7 more
Jun 30, 2022
COVID-19 Trial in Taipei (Ropeginterferon alfa-2b, SOC)
Not yet recruiting
- COVID-19
- Ropeginterferon alfa-2b
- SOC
-
Taipei, TaiwanNational Taiwan University Hospital
Apr 9, 2023
Hepatitis D Trial in Taipei (Ursodeoxycholic acid, Ropeginterferon alfa-2b, Tenofovir Alafenamide)
Not yet recruiting
- Hepatitis D
- Ursodeoxycholic acid
- +2 more
-
Taipei, Taiwan
- +1 more
Jul 19, 2022
Hepatitis C, Chronic Trial in Taiwan (PEGASYS 180 µg Q1W, P1101 180 µg Q1W, 48 doses, P1101 270µg Q1W, 48 doses)
Completed
- Hepatitis C, Chronic
- PEGASYS 180 µg Q1W
- +3 more
-
Changhua, Taiwan
- +12 more
Oct 7, 2021
COVID-19 Trial in Taipei (P1101 (Ropeginterferon alfa-2b), SOC)
Active, not recruiting
- COVID-19
- P1101 (Ropeginterferon alfa-2b)
- SOC
-
Taipei, TaiwanNational Taiwan University Hospital
Mar 13, 2023
Polycythemia Vera (PV) Trial in Japan (P1101, Low-dose aspirin, Phlebotomy)
Completed
- Polycythemia Vera (PV)
- P1101
- +2 more
-
Toon-shi, Ehime, Japan
- +7 more
Dec 8, 2021
Polycythemia Vera Trial in China (Ropeginterferon alfa-2b)
Active, not recruiting
- Polycythemia Vera
- Ropeginterferon alfa-2b
-
Beijing, China
- +13 more
Aug 1, 2022
Chronic Hepatitis B Infection, Chronic Hepatitis D Infection Trial in Taipei City, Taipei city, Taoyuan city (P1101 + Nivolumab
Recruiting
- Chronic Hepatitis B Infection
- Chronic Hepatitis D Infection
- P1101 + Nivolumab + Entecavir
-
Taipei City, Taiwan
- +3 more
Sep 15, 2021
Chronic Hepatitis C Virus Infection Trial in China, Korea, Republic of, Taiwan (P1101 + Ribavirin, PEG-Intron + Ribavirin)
Completed
- Chronic Hepatitis C Virus Infection
- P1101 + Ribavirin
- PEG-Intron + Ribavirin
-
Beijing, China
- +38 more
Jan 14, 2022
Essential Thrombocythemia Trial in Worldwide (Ropeginterferon alfa-2b, Anagrelide)
Recruiting
- Essential Thrombocythemia
- Ropeginterferon alfa-2b
- Anagrelide
-
Phoenix, Arizona
- +60 more
Dec 30, 2021
Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma Trial in Chicago, Rochester, Cleveland (Venetoclax, Umbralisib, Ublituximab)
Terminated
- Chronic Lymphocytic Leukemia
- Non-Hodgkin Lymphoma
- Venetoclax
- +3 more
-
Chicago, Illinois
- +2 more
Aug 19, 2022
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,
Active, not recruiting
- Prolymphocytic Leukemia
- +2 more
- Ibrutinib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Dec 7, 2022
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)
Recruiting
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Rituximab
- Zanubrutinib
-
Houston, TexasM D Anderson Cancer Center
Jul 9, 2022
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1
Active, not recruiting
- Ann Arbor Stage I Grade 1 Follicular Lymphoma
- +3 more
- Clinical Observation
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,
Recruiting
- Recurrent Diffuse Large B-Cell Lymphoma
- +3 more
- Laboratory Biomarker Analysis
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 26, 2022
Metastatic Colorectal Carcinoma, Metastatic Malignant Tumor in the Liver, Stage IV Colorectal Cancer AJCC v8 Trial (biological,
Not yet recruiting
- Metastatic Colorectal Carcinoma
- +3 more
- Bevacizumab
- +11 more
- (no location specified)
May 9, 2023
Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial
Not yet recruiting
- Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
- Polymorphic Post-Transplant Lymphoproliferative Disorder
- Biopsy
- +5 more
-
New Brunswick, New Jersey
- +2 more
Mar 23, 2023
Polycythemia Vera Trial in Italy (AOP2014, Phlebotomies, ASA)
Active, not recruiting
- Polycythemia Vera
- AOP2014
- +2 more
-
San Giovanni Rotondo, (FG) Puglia, Italy
- +22 more
Jan 10, 2023